X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RAD-18-002 (Radspherin), is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. It is under phase 1/2 clinical development for treatmemt of peritoneal carcinomatosis from ovarian cancer.
Lead Product(s): Alpha-emitting Radionuclide Therapy
Therapeutic Area: Oncology Product Name: Radspherin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Radspherin (alpha-emitting radioactive micro particle suspension) is a novel treatment principle especially designed to give local radiation to the surface of the abdominal cavity. It is being evaluated for patients with peritoneal carcinomatosis from colorectal cancer.
Lead Product(s): Alpha-emitting Radionuclide Therapy
Therapeutic Area: Oncology Product Name: Radspherin
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2023
Details:
RAD-18-002 (Radspherin) ®, is a new alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities, has in animal models been shown to cause reduction in tumour cell growth and a significant increased survival.
Lead Product(s): Radspherin
Therapeutic Area: Oncology Product Name: RAD-18-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
The biodistribution of Radspherin, consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension, showed relatively even peritoneal distribution, and no patients had compartments of the abdominal cavity without radioactivity.
Lead Product(s): Radspherin
Therapeutic Area: Oncology Product Name: RAD-18-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Radspherin®, a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities and its versatility allows it to be deployed for the treatment of a variety of cancer indications.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Radspherin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2021
Details:
7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Radspherin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2021
Details:
The phase 1 dose escalation trial is designed to assess the dose, safety and tolerability of Radspherin® administered into the intraperitoneal cavity in subjects with peritoneal carcinomatosis from colorectal carcinoma following complete cytoreductive surgery and HIPEC.
Lead Product(s): Radium-224
Therapeutic Area: Oncology Product Name: Radspherin
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
